Venture capital markets continue to show high interest in companies with a focus on regenerative medicine from Europe and the US.
Since 2017 the market has shown exceptional growth, as funding volumes increased threefold to ca. EUR 1,000m in 2021.
Especially gene and cell therapies in the Biotech sector continue to be main drivers in regenerative medicine. However, funding volumes of MedTech companies also have shown remarkable growth in recent years.
These observations clearly indicate the future potential that is attributed to the market of regenerative medicine.
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: